Last year, the Department for Work and Pensions (DWP) excluded extending the £20 a week Universal Credit pandemic uplift to disabled people on legacy benefits like ESA. Today, The Court of Appeal ruled that they did not act unlawfully.
A recent study using the UK MS Register found less than a third of people with MS have been offered a treatment for fatigue as part of their routine care. We’ve committed to raise funds for a new project to help address this.
Octopus is a new clinical trial for primary and secondary progressive MS. After some delays, it’s now had the official thumbs up from the regulators. This important milestone brings us another step closer to the trial getting started.
The StarMS trial is comparing HSCT (haemotopoietic stem cell transplantation) with other highly effective treatments for relapsing MS. HSCT is a treatment for MS that involves using chemotherapy to remove harmful immune cells. Your own stem cells are then used to regrow the immune system.
Results of two clinical trials for relapsing remitting MS showed new drug ublituximab was better than the existing treatment teriflunomide (Aubagio) at reducing relapses. And people taking ublituximab developed fewer new lesions.
Today we released some new research on how rising energy bills are impacting people with MS. Hear from Kelly who lives with MS. And find out what we're asking the new Prime Minister to do in September.
Today the UK Government announced to the BBC they're delaying a decision to give Evusheld to vulnerable groups. This is until the results of a review into the drug by the National Institute for Health and Care Excellence (NICE).